🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT04771728
Recruiting Phase 4

A Prospective, Randomized Controlled Study of the Probiotics as Adjuvant Treatment for Bacterial Vaginosis

NCT04771728 · tracked via the Priya Life Science China tracker
Sponsor
Peking University Shenzhen Hospital
Phase
Phase 4
Started
2020-02-01
Last updated
2025-06-12

Condition(s) studied

Bacterial Vaginosis

Investigational drug(s) / intervention(s)

Metronidazole vaginal suppositoriesMetronidazole vaginal suppositories and Probiotics(Umeta-mimi)

Metronidazole vaginal suppositories: Metronidazole vaginal suppositories (200 mg,2 capsules per day,7 days )

Metronidazole vaginal suppositories and Probiotics(Umeta-mimi): Metronidazole vaginal suppositories (200 mg,2 capsules per day,7 days ) and Oral pobiotics(Umeta-mimi,5×109cfu per day,30 days)

Study summary

The investigators are trying to determine if oral Probiotics(Umeta-mimi,30 days) with Metronidazole vaginal suppositories (7 days) is better than using Metronidazole vaginal suppositories(7 days) only in preventing the recurrence of bacterial vaginosis

Eligibility

Sex
FEMALE
Min age
18 Years
Max age
55 Years
Healthy volunteers
Accepted
Inclusion Criteria: 1. Aged 18 to 55 years old, with history of sexual activity, 2. Amsel criterion for diagnosing BV 3. Sign informed consent Exclusion Criteria: 1. History of systemic organic diseases or psychiatric diseases 2. Planning for or during pregnancy, lactation, menstruation 3. within 5 days of onset of the disease, any antibiotics has been used 4. Long-term use of contraceptives or immunosuppressant 5. Anaphylactic constitution or allergic to known ingredients of research drugs 6. No same fixed partner (RSP) before and after treatment

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Peking University Shenzhen Hosptal Shenzhen Guangdong Recruiting

More Peking University Shenzhen Hospital trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04771728 on ClinicalTrials.gov ↗ ← All trials in China